Article
Allelic burden of Janus kinase 2 in a 6-month course of therapy for myeloproliferative neoplasms.
Molecular biology reports - 1 Jul 2023
Demiriz Itır Şirinoğlu, Kazanci Mehmet Hanifi, Menfaatli Esra, Jafari-Gharabaghlou Davoud, Zarghami Nosratollah
Abstract excerpt
BACKGROUND: Janus kinase 2 (JAK2) V617F gene mutation is an important marker for the diagnosis of Philadelphia negative Myeloproliferative neoplasms (MPN) which is subdivided into Polycythemia Vera (PV), Primary Myelofibrosis (PMF), and Essential Thrombocythemia (ET). The aim here is to investigate the JAK2 allele burden of the patients diagnosed with the subgroups of MPN and to demonstrate the alterations of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.